

Akebia Therapeutics Beat Consensus Estimates
Thursday, May 8, 2025 at 7:00 AM ET
Akebia Therapeutics (AKBA) reported earnings of $0.03 per share on revenue of $57.34 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.03 per share on revenue of $45.21 million. The company beat consensus estimates by 200.00% while revenue grew 75.84% on a year-over-year basis.
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$0.03
Earnings Whisper®
-
Consensus Estimate
$-0.03
Earnings Surprise
Earnings Growth
Reported Revenue
$57.34 Mil
Revenue Estimate
$45.21 Mil
Revenue Surprise
Revenue Growth